Marshall Wace, LLP Celldex Therapeutics, Inc. Transaction History

Marshall Wace, LLP

$63.3 Billion
Q1 2024

A detailed history of Marshall Wace, LLP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 898,800 shares of CLDX stock, worth $33.3 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

898,800

Previous 1,280,084 29.79%

Holding current value

$33.3 Million

Previous $50.8 Million 25.7%

% of portfolio

0.06%

Previous 0.09%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$35.22 - $51.88 $13.4 Million - $19.8 Million	-381,284 Reduced 29.79%	898,800 $37.7 Million
Q4 2023 Feb 14, 2024	BUY	$22.61 - $40.65 $16.8 Million - $30.2 Million	741,765 Added 137.79%	1,280,084 $50.8 Million
Q3 2023 Nov 14, 2023	BUY	$25.45 - $37.46 $6.33 Million - $9.32 Million	248,796 Added 85.93%	538,319 $14.8 Million
Q2 2023 Aug 14, 2023	SELL	$30.29 - $38.28 $1.34 Million - $1.69 Million	-44,143 Reduced 13.23%	289,523 $9.82 Million
Q1 2023 May 15, 2023	SELL	$34.78 - $47.43 $11.6 Million - $15.8 Million	-333,083 Reduced 49.96%	333,666 $12 Million

Q4 2022 Feb 14, 2023	BUY	$27.78 - $45.38 $389,697 - $636,590	14,028 Added 2.15%	666,749 $29.7 Million
Q3 2022 Nov 14, 2022	BUY	$22.7 - $37.57 $14.4 Million - $23.8 Million	632,698 Added 3159.86%	652,721 $18.3 Million
Q2 2022 Aug 15, 2022	BUY	$20.5 - $37.33 $410,471 - $747,458	20,023 New	20,023 $539,000
Q2 2021 Aug 13, 2021	SELL	$20.71 - $35.37 $426,211 - $727,914	-20,580 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.19 - $29.91 $138,537 - $255,939	8,557 Added 71.17%	20,580 $423,000
Q4 2020 Feb 16, 2021	BUY	$14.99 - $22.75 $180,224 - $273,523	12,023 New	12,023 $211,000

Others Institutions Holding CLDX

# of Institutions

207

Shares Held

61.2M

Call Options Held

291K

Put Options Held

246K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.73B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Celldex Therapeutics, Inc. Transaction History